Joakim Tedroff
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial.
Journal: Movement disorders clinical practice
Published: November 04, 2024
Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia.
Journal: The European journal of neuroscience
Published: September 26, 2024
First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: March 08, 2021
A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.
Journal: Pharmacology research & perspectives
Published: November 16, 2020
Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.
Journal: The journal of headache and pain
Published: May 29, 2020
(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent.
Journal: The Journal of pharmacology and experimental therapeutics
Published: April 02, 2020
Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission.
Journal: The Journal of pharmacology and experimental therapeutics
Published: January 02, 2020
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease.
Journal: The Journal of pharmacology and experimental therapeutics
Published: December 18, 2019
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: December 14, 2019
Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial.
Journal: NPJ Parkinson's disease
Published: June 08, 2018
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
Journal: Journal of Huntington's disease
Published: February 27, 2018
Last Updated: 09/26/2026